Prostate cancer, the PSA test and academic detailing in Australian general practice: An economic evaluation

Australian and New Zealand Journal of Public Health

Volumn 29, Issue 4, 2005, Pages 349-357

  Stone, Christine A ^a   May, Frank W ^b,c   Pinnock, Carole B ^c   Elwood, Mark ^d   Rowett, Debra S ^a,c  

^a Planning and Review   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

^d National Cancer Control Initiative   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EDUCATION PROGRAM; GENERAL PRACTICE; GENERAL PRACTITIONER; GOVERNMENT; HEALTH CARE COST; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MONTE CARLO METHOD; PREDICTION; PROSTATE CANCER;

EID: 27944492402     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-842X.2005.tb00206.x     Document Type: Article

References (45)

1. Australian Institute of Health and Welfare. Cancer in Australia 1997: Incidence and Mortality Data for 1997 and Selected Data for 1998 and 1999. Canberra (Aust): AIHW; 2000. Cancer Series No.: 15.
2. Mathers C, Vos T, Stevenson C. The Burden of Disease and Injury in Australia. Canberra (Aust): Australian Institute of Health and Welfare; 1999.
3. Mathers C, Penm R, Sanson-Fisher R, Carter R, Campbell E. Health System Costs of Cancer in Australia 1993-94. Canberra (Aust): Australian Institute of Health and Welfare; 1998. Health and Welfare Expenditure Series No.: 4.
4. Smith D, Armstrong B. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust. 1998;169:17-20.
5. Weller D, Sirenko A, Hiller J. Screening for Prostate Cancer in the Australian Population. A Review for the Australian Health Technology Advisory Committee. Canberra (Aust): National Health and Medical Research Council; 1995.
6. Weller D, Pinnock C, Alderman C, Moss J, Doust J. Screening for Prostate Cancer - Update of the 1996 AHTAC Report. Canberra (Aust): Health and Human Services; 1999.
7. Cancer Strategies Group. Priorities for Action in Cancer Control 2001-2003. Canberra (Aust): Commonwealth Department of Health and Ageing; 2001.
8. Carter R, Stone C, Vos T, Hocking J, Mihalopoulos C, Peacock S, et al. [CHE publications page on the Internet]. Melbourne (Aust): Centre for Health Program Evaluation; 2000 [cited 2005 June 21]. Trial of Program Budgeting and Marginal Analysis (PBMA) to Assist Cancer Control Planning in Australia. Full Report. Available from: http://www.buseco.monash.edu.au/centres/che/pubs/rr19full.pdf
9. Carter R, Stone C, Vos T, Hocking J, Mihalopoulos C, Peacock S, et al. [CHE publications page on the Internet]. Melbourne (Aust): Centre for Health Program Evaluation; 2000 [cited 2005 June 21]. Trial of Program Budgeting and Marginal Analysis (PBMA) to Assist Cancer Control Planning in Australia. Summary Report. Available from: http://www.buseco.monash.edu.au/centres/che/pubs/rr19summ.pdf
10. Weller D, May F, Rowett D, Esterman A, Pinnock C, Nicholson S, et al. Promoting better use of the PSA test in general practice: randomized controlled trial of educational strategies based on outreach visits and mailout. Fam Pract. 2003;20:655-61.
11. Gold M, Siegal J, Russel L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
12. Pinnock C, Weller D, Marshall V. Prostate cancer testing in South Australia: a community study. Med J Aust. 1998;169:25-8.
13. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ. 2000;162(7):987-92.
14. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(11):917-29.
15. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. J Am Med Assoc. 2000;283(24):3217-22.
16. Holmes-Rovner M, Llewellyn-Thomas H, Entwistle V, Coulter A, O'Connor A, Rovner DR. Patient choice modules for summaries of clinical effectiveness: a proposal. Br Med J. 2001;322(7287):664-7.
17. Thomson O'Brien M, Oxman A, Davis D, Haynes R, Freemantle N, Harvey E. Educational outreach visits: effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Database Systematic Review, Issue 4; 1997. Oxford (UK): Update Software; 2005.
18. Silagy C, May F, Avorn J. An Overview of Current Practices of Academic Detailing in Australia and Internationally. Canberra (Aust): Commonwealth Department of Health; 1997.
19. Murray C, Lopez A. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge (UK): Harvard University Press; 1996.
20. Vos T, Begg S. The Victorian Burden of Disease Study: Mortality. Melbourne (Aust): Public Health and Development Division, Victorian Government Department of Human Services; 1999.
21. Stouthard M, Essink-Bot M, Bonsel G, Barendregt JPK. Disability Weights for Diseases in the Netherlands. Rotterdam (NLD): Department of Public Health, Erasmus University; 1997.
22. Australian Institute of Health and Welfare. Cancer in Australia 1996: Incidence and Mortality Data for 1996 and Selected Data for 1997 and 1998. Canberra (Aust): AIHW; 1999. AIHW Catalogue No.: CAN 7.
23. May FW, Rowett DR. DATIS: academic detailing to general practitioners - techniques, problems and outcomes. In: McGavock H, editor. Handbook of Drug Use Methodology. Newcastle-upon-Tyne (UK): UK Drug Utilization Research Group; 2000. p. 181.
24. MBS Schedules. Canberra (Aust): Commonwealth Department of Health and Aged Care; 1999.
25. ®ISK: advanced risk analysis for spreadsheets [computer program]. Version 3.5. New York: Palisade; 1996.
26. Australian Institute of Health and Welfare. Australia's Health Services Expenditure to 1998-99. Canberra (Aust): AIHW; 2000. Health Expenditure Bulletin No.: 16.
27. Stone CA, Carter RC, Vos T, John JS. Colorectal cancer screening in Australia: an economic evaluation of a potential biennial screening program using faecal occult blood tests. Aust N Z J Public Health. 2004;28(3):273-82.
28. Black N. Evidence based policy: proceed with care. Br Med J. 2001;323(7307):275-9.
29. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6):iii-iv, 1-72.
30. Stevens SA, Cockburn J, Hirst S, Jolley D. An evaluation of educational outreach to general practitioners as part of a statewide cervical screening program. Am J Public Health. 1997;87(7):1177-81.
31. Young JM, D'Este C, Ward JE. Improving family physicians' use of evidence-based smoking cessation strategies: a cluster randomization trial. Prev Med. 2002;35(6):572-83.
32. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ. 1995;153(10):1423-31.
33. Schroder F. Detection of prostate cancer. Screening of the whole population has not yet been shown to be worthwhile. Br Med J. 1995;310:140-1.
34. Schroder F, Kranse R, Rietbergen J, Hoedemaeker R, Kirkels W. The European randomised study of screening for prostate cancer (ERSPC): An update. Eur Urol. 1999;35:539-543.
35. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119(9):914-23.
36. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295-300.
37. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;1781-8.
38. Perron L, Moore L, Bairati I, Bernard P, Meyer F. PSA screening and prostate cancer mortality. CMAJ. 2002;166(5):586-91.
39. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J. 2002;325(7367):740-5.
40. May F, Rowett D, Pinnock C, Esterman A. Developing national strategies for improvement of the use of the prostate-specific antigen test in the Australian Community: Final report to the Commonwealth Department of Health and Ageing. Canberra (Aust): Commonwealth Department of Health and Ageing, 2004. Personal communication.
41. Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. Printed educational materials: effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Database Systematic Review, Issue 4, 2001. Oxford (UK): Update Software; 2001.
42. Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function - the most important disease-specific distress for patients with prostate cancer. Br J Cancer. 1996;73(11):1417-21.
43. Lee R, Penson DF. Treatment outcomes in localized prostate cancer: a patient-oriented approach. Semin Urol Oncol. 2002;20(1):63-73.
44. Lubeck DP, Grossfeld GD, Carroll PR. A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology. 2002;60(3 Suppl 1):72-7; discussion 77-8.
45. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790-6.